Drug targets for amyloidosis.
Kolstoe
Simon E
SE
Centre for Amyloidosis and Acute Phase Proteins, Department of Medicine, University College London, Rowland Hill Street, London NW3 2PF, UK.
Wood
Steve P
SP
D000686:Amyloidosis / Q000188:drug therapy* / Q000209:etiology / Q000378:metabolism; D000818:Animals; D002264:Carboxylic Acids / Q000494:pharmacology / Q000627:therapeutic use; D003432:Cross-Linking Reagents / Q000494:pharmacology / Q000627:therapeutic use; D016503:Drug Delivery Systems / Q000379:methods*; D006801:Humans; D008954:Models, Biological; D008958:Models, Molecular; D019636:Neurodegenerative Diseases / Q000188:drug therapy* / Q000209:etiology / Q000378:metabolism; D011228:Prealbumin / Q000378:metabolism; D011485:Protein Binding; D055503:Protein Multimerization / Q000502:physiology; D011759:Pyrrolidines / Q000494:pharmacology / Q000627:therapeutic use; D000683:Serum Amyloid P-Component / Q000378:metabolism
D002264:Carboxylic Acids; D003432:Cross-Linking Reagents; D011228:Prealbumin; D011759:Pyrrolidines; C455899:R-1-(6-(R-2-carboxypyrrolidin-1-yl)-6-oxohexanoyl)pyrrolidine-2-carboxylic acid; D000683:Serum Amyloid P-Component